GLP-1 Research

Tirzepatide vs Semaglutide: Research Differences

Tirzepatide vs Semaglutide — how the dual GLP-1/GIP agonist compares to the GLP-1 mono-agonist in published research.

Research use only. All products discussed are sold strictly for laboratory research. Not for human or animal consumption, diagnosis, cure, or treatment. No dosing or administration guidance is provided.

Tirzepatide vs Semaglutide at a glance

Both peptides are studied in metabolic and weight-management research, but they engage different receptor sets. Semaglutide is a GLP-1 receptor agonist; Tirzepatide is a dual GLP-1 / GIP receptor agonist. That mechanistic difference underlies the divergent trial outcomes.

Receptor pharmacology

Semaglutide activates GLP-1 receptors only. Tirzepatide activates both GLP-1 and GIP receptors, giving it a broader incretin footprint in published preclinical and clinical research.

Published trial data

STEP trials (Semaglutide) and SURMOUNT trials (Tirzepatide) form the primary evidence base. Read our full Tirzepatide research guide and Semaglutide research guide for the trial-by-trial breakdown.

Sourcing for research

Our Tirzepatide research peptide and Semaglutide research peptide ship third-party HPLC tested with a Certificate of Analysis on request.

Disclaimer

For laboratory research use only. Not for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease.

Frequently asked questions

Is Tirzepatide stronger than Semaglutide?

Published trials suggest Tirzepatide produces larger effect sizes on the studied metabolic endpoints, but the comparison depends on dose and protocol.

Are they interchangeable in a research study?

No. They engage different receptor sets, so substitutions change the pharmacology of the experiment.

Research use only. All products discussed are sold strictly for laboratory research. Not for human or animal consumption, diagnosis, cure, or treatment. No dosing or administration guidance is provided.

← Back to blog